TSS
SABS icon

Two Sigma Securities’s SAB Biotherapeutics SABS Stock Holding History

Two Sigma Securities’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,287
Closed -$10.7K – 3404
2023
Q2 		$10.7K Sell
1,287
-57
-4% -$467 ﹤0.01% 2587
2023
Q1 		$5.91K Buy
+1,344
New +$8.5K ﹤0.01% 2514

Other funds holding SABS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FPB
First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return
PFO
Pathstone Family Office Englewood, New Jersey $13.1B AUM 21.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
IFAM
Institutional & Family Asset Management Fort Collins, Colorado $654M AUM 12.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Securities's SABS Position: Q3 2023 in Review

Two Sigma Securities sold out of SAB Biotherapeutics (SABS) in Q3 2023, closing a stake of 1,287 shares — an estimated $10.7K sold.

Two Sigma Securities first reported a position in SABS in Q1 2023 and held it in 2 quarters. The position peaked at $10.7K in Q2 2023. 34 funds tracked by Wall St. Rank hold SABS as of Q3 2023.

  • Two Sigma Securities reported no remaining SAB Biotherapeutics position as of Q3 2023 after selling out during the quarter.
  • Two Sigma Securities sold 1,287 SAB Biotherapeutics shares in Q3 2023, an estimated $10.7K.
  • Two Sigma Securities first reported a position in SAB Biotherapeutics in Q1 2023 and held it in 2 quarters.
  • Two Sigma Securities's SAB Biotherapeutics position peaked at $10.7K in Q2 2023.
  • 34 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2023.

Based on Two Sigma Securities's 13F filing for Q3 2023, filed 14 Nov 2023.